Germline Genetic Testing for Hereditary Breast and Ovarian Cancer : Current Concepts in Risk Evaluation
Copyright © 2023 Cold Spring Harbor Laboratory Press; all rights reserved..
Our understanding of hereditary breast and ovarian cancer has significantly improved over the past two decades. In addition to BRCA1/2, pathogenic variants in several other DNA-repair genes have been shown to increase the risks of breast and ovarian cancer. The magnitude of cancer risk is impacted not only by the gene involved, but also by family history of cancer, polygenic risk scores, and, in certain genes, pathogenic variant type or location. While estimates of breast and ovarian cancer risk associated with pathogenic variants are available, these are predominantly based on studies of high-risk populations with young age at diagnosis of cancer, multiple primary cancers, or family history of cancer. More recently, breast cancer risk for germline pathogenic variant carriers has been estimated from population-based studies. Here, we provide a review of the field of germline genetic testing and risk evaluation for hereditary breast and ovarian cancers in high-risk and population-based settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Cold Spring Harbor perspectives in medicine - (2023) vom: 27. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yadav, Siddhartha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 27.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1101/cshperspect.a041318 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366419625 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366419625 | ||
| 003 | DE-627 | ||
| 005 | 20231229124317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/cshperspect.a041318 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM366419625 | ||
| 035 | |a (NLM)38151326 | ||
| 035 | |a (PII)a041318 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yadav, Siddhartha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Germline Genetic Testing for Hereditary Breast and Ovarian Cancer |b Current Concepts in Risk Evaluation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Cold Spring Harbor Laboratory Press; all rights reserved. | ||
| 520 | |a Our understanding of hereditary breast and ovarian cancer has significantly improved over the past two decades. In addition to BRCA1/2, pathogenic variants in several other DNA-repair genes have been shown to increase the risks of breast and ovarian cancer. The magnitude of cancer risk is impacted not only by the gene involved, but also by family history of cancer, polygenic risk scores, and, in certain genes, pathogenic variant type or location. While estimates of breast and ovarian cancer risk associated with pathogenic variants are available, these are predominantly based on studies of high-risk populations with young age at diagnosis of cancer, multiple primary cancers, or family history of cancer. More recently, breast cancer risk for germline pathogenic variant carriers has been estimated from population-based studies. Here, we provide a review of the field of germline genetic testing and risk evaluation for hereditary breast and ovarian cancers in high-risk and population-based settings | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Couch, Fergus J |e verfasserin |4 aut | |
| 700 | 1 | |a Domchek, Susan M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cold Spring Harbor perspectives in medicine |d 2012 |g (2023) vom: 27. Dez. |w (DE-627)NLM21597185X |x 2157-1422 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:27 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/cshperspect.a041318 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 27 |c 12 | ||